Ramos Kathleen J, Quon Bradley S, Psoter Kevin J, Lease Erika D, Mayer-Hamblett Nicole, Aitken Moira L, Goss Christopher H
University of Washington Medical Center, Division of Pulmonary and Critical Care Medicine, Department of Medicine, Seattle, WA, United States.
Centre for Heart Lung Innovation, University of British Columbia and St. Paul's Hospital, Vancouver, BC, Canada.
J Cyst Fibros. 2016 Mar;15(2):196-203. doi: 10.1016/j.jcf.2015.11.005. Epub 2015 Dec 17.
Lung transplantation is an intervention that improves survival for adult patients with cystic fibrosis (CF). Some patients with CF are never referred for lung transplant evaluation despite meeting physiologic criteria for referral.
We performed a retrospective analysis of adult patients (≥18years of age) in the Cystic Fibrosis Foundation Patient Registry (CFFPR), eligible for their first evaluation for lung transplantation during the years 2001-2008 based on FEV1<30% predicted in two consecutive years.
Within the CFFPR, 1240 patients met eligibility criteria. Eight hundred and nine (65.2%) were referred for lung transplant evaluation, and 431 (34.8%) were not referred. In a multivariable model, Medicaid insurance (OR 1.79, 95% CI 1.29-2.47), older age (per 5year increase; OR 1.25, 95% CI 1.13-1.39), lack of high school graduate education (OR 2.27, 95% CI 1.42-3.64), and Burkholderia cepacia complex sputum culture positivity (OR 2.48, 95% CI 1.50-4.12) were associated with non-referral, while number of pulmonary exacerbations (OR 0.93, 95% CI 0.87-0.99) and supplemental oxygen use (OR 0.59, 95% CI 0.43-0.81) were associated with increased referral.
Despite meeting lung function criteria for lung transplant evaluation, 35% of patients with CF had not yet been referred to a lung transplant center. Predictors of non-referral included markers of low socioeconomic status, older age and B. cepacia complex sputum culture. Further work is needed to understand the outcomes for non-referred patients in order to refine referral recommendations in this population.
肺移植是一种可提高成年囊性纤维化(CF)患者生存率的干预措施。一些符合生理转诊标准的CF患者从未被转诊进行肺移植评估。
我们对囊性纤维化基金会患者登记处(CFFPR)中年龄≥18岁的成年患者进行了回顾性分析,这些患者在2001年至2008年期间基于连续两年FEV1<预测值的30%符合首次肺移植评估条件。
在CFFPR中,1240例患者符合入选标准。809例(65.2%)被转诊进行肺移植评估,431例(34.8%)未被转诊。在多变量模型中,医疗补助保险(比值比[OR]1.79,95%置信区间[CI]1.29 - 2.47)、年龄较大(每增加5岁;OR 1.25,95% CI 1.13 - 1.39)、未接受高中教育(OR 2.27,95% CI 1.42 - 3.64)以及洋葱伯克霍尔德菌复合菌属痰培养阳性(OR 2.48,95% CI 1.50 - 4.12)与未转诊相关,而肺部加重发作次数(OR 0.93,95% CI 0.87 - 0.99)和使用补充氧气(OR 0.59,95% CI 0.43 - 0.81)与转诊增加相关。
尽管符合肺移植评估的肺功能标准,但35%的CF患者尚未被转诊至肺移植中心。未转诊的预测因素包括社会经济地位低的指标、年龄较大和洋葱伯克霍尔德菌复合菌属痰培养。需要进一步开展工作以了解未转诊患者的结局,从而完善该人群的转诊建议。